terminal betWe investated the ability of BET bromodomain small molecule inhibitors to reduce the β-cell response to the proinflammatory cytokine interleukin 1 betaA novel, weak bromo and extra terminal domain (BET) bromodomain fragment land to a potent and selective second bromodomain (BD2) inhibitor.